Based on reports highlighting the oncogenic role of Beclin1 in ER+ breast cancer, miR-221-induced inhibition of Beclin1 would theoretically inhibit ER+ breast carcinogenesis and promote tamoxifen sensitivity in ER+ breast cancers. Here, BECN1 is linked to breast carcinoma.